News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Wanbang Biopharmaceuticals In-licenses Diabetes Drug Rights From Sirona Biochem Of Canada


1/27/2014 10:01:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

January 27, 2014 -- Wanbang Biopharma in-licensed the China rights to develop a pre-clinical diabetes drug discovered by Sirona Biochem of Canada. Wanbang will make up to $9.5 million in upfront and milestone payments plus royalties. The drug is a member of the SGLT2 class of diabetes drugs that inhibit glucose reabsorption from the kidneys. Wanbang, a division of Fosun Pharma, is active in diabetes treatments. More details....

Stock Symbols: (TSX: SBM; OTCQS: SRBCF) (SHA: 600196; HK: 02196)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES